Branded urofollitropin

Pharmasure has launched Fostimon (urofollitropin), licensed for the treatment of anovulatory infertility unresponsive to clomifene, and controlled ovarian hyperstimulation to induce multiple follicles for IVF, GIFT and ZIFT.

Fostimon is a highly purified follicle stimulating hormone (FSH), obtained from human menopausal gonadotropin (HMG). The main effect of FSH is the development and maturation of de Graaf follicles.

Fostimon is available in two strengths, 75iu and 150iu, and is presented in packs of 10 vials (plus solvent in ampoules) for reconstitution. The most commonly reported adverse effects include ovarian hyperstimulation, headache, constipation, abdominal distension and pain.

Further information: Pharmasure 01923 233113

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Experts urge vitamin D supplementation and call for research into possible COVID-19 benefits
Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

New rapidly acting insulin launched

New rapidly acting insulin launched

Lyumjev is a new 'ultra rapidly acting' formulation...